Back to Search
Start Over
Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials
- Source :
- Iranian Journal of Public Health, Vol 48, Iss 9 (2019)
- Publication Year :
- 2019
- Publisher :
- Tehran University of Medical Sciences, 2019.
-
Abstract
- Background: Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) as the commonly used renin-angiotensin aldosterone system inhibitor are widely used in patients with IgA nephropathy (IgAN), but the effect is controversy. In this study, we used a meta-analysis to evaluate the efficacy and safety of ACEI and/or ARB for the patients with IgAN. Methods: Two investigators independently searched the PubMed, EMBASE, the Cochrane Library, EBSCO, and Wiley databases without language restrictions. We collected the clinical randomized controlled trials (RCTs) on “ACEI and/or ARB for the patients with IgAN” published before December 31, 2018, and performed data extraction and quality analysis on the included studies, and analyzed data using RevMan 5.2 software. Results: A total of 10 RCTs (635 patients) were included in our analysis. Alone use of ACEI (MD=-0.75, 95%CI: -1.28-0.21, P=0.006) or ARB (MD=-0.56, 95%CI: -0.82-0.30, P< 0.001) or a combination of ACEI and ARB (MD=-0.63, 95%CI: -0.87-0.38, P
Details
- Language :
- English
- ISSN :
- 22516085 and 22516093
- Volume :
- 48
- Issue :
- 9
- Database :
- Directory of Open Access Journals
- Journal :
- Iranian Journal of Public Health
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.30edc2708984f8dadba0b0b66f473e2
- Document Type :
- article
- Full Text :
- https://doi.org/10.18502/ijph.v48i9.3014